文献速递肿瘤 PET/CT

实体肿瘤患者脾脏CXCR4表达的[68Ga]Pentixafor PET研究

Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients.
PubMed 文献 · EJNMMI Res · 2021-08-21

该回顾性研究分析了145例涵盖27种癌症类型的实体瘤患者的[68Ga]Pentixafor PET图像与病历,探究脾脏示踪剂摄取与临床特征及预后的关联。结果显示脾脏摄取与疾病分期及临床结局无关,但在神经内分泌肿瘤、非小细胞肺癌和小细胞肺癌中,高脾脏摄取与白细胞和/或血小板计数呈正相关。

要点

  • 脾脏[68Ga]Pentixafor摄取与实体瘤患者疾病分期及临床结局无关。
  • 神经内分泌肿瘤、非小细胞肺癌和小细胞肺癌中,脾脏高摄取与白细胞和/或血小板计数正相关。
  • 无特定肿瘤类型显示脾脏摄取显著高于其他类型或对照组。

核心结论

  • 脾脏[68Ga]Pentixafor摄取与实体瘤患者疾病分期和临床结局无关。
  • 在神经内分泌肿瘤、非小细胞肺癌和小细胞肺癌中,脾脏高摄取与白细胞和/或血小板计数正相关,提示脾脏CXCR4表达可能在部分实体瘤的全身免疫/炎症中起作用。

研究设计与样本

  • 回顾性研究,纳入145例实体瘤患者,涵盖27种癌症类型,分析[68Ga]Pentixafor PET图像与病历。

主要发现

  • 在全队列及肾上腺癌、促结缔组织增生性小圆细胞肿瘤、神经内分泌肿瘤、非小细胞肺癌、小细胞肺癌和胰腺腺癌亚组中,无进展生存期、总生存期和缓解状态均无差异。
  • 无肿瘤类型显示脾脏[68Ga]Pentixafor摄取特别高于其他类型或对照组。
  • 神经内分泌肿瘤、非小细胞肺癌和小细胞肺癌中,脾脏高摄取与白细胞和/或血小板计数呈正相关。

临床怎么用

  • 脾脏[68Ga]Pentixafor摄取不宜作为实体瘤分期或预后判断的独立指标。
  • 在神经内分泌肿瘤、非小细胞肺癌和小细胞肺癌中,脾脏高摄取可能提示需关注血细胞计数及免疫/炎症状态。

局限性

  • 回顾性研究设计。
  • 样本来自27种癌症类型,各亚组样本量可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The chemokine receptor CXCR4 is frequently overexpressed and associated with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently, CXCR4 molecular imaging using the CXCR4-specific positron emission tomography (PET) tracer Pentixafor ([68Ga]Pentixafor) has become a well-established method to non-invasively measure CXCR4 expression in vivo. In previous Pentixafor imaging studies, highly variable CXCR4 tracer uptake to the spleen was observed. RESULTS: We investigated the hypothesis that enhanced spleen [68Ga]Pentixafor uptake and thus CXCR4 expression in patients with solid tumors would indicate an activated spleen state and/or an association with clinical and prognostic features and survival parameters. In this retrospective study, [68Ga]Pentixafor-PET images and patient records of 145 solid tumor patients representing 27 cancer entities were investigated for an association of spleen [68Ga]Pentixafor uptake and clinical characteristics and outcome. Based on this assessment, we did not observe differences in clinical outcomes, measured by progression-free survival, overall survival and remission status neither within the entire cohort nor within subgroups of adrenal cancer, desmoplastic small round cell tumor, neuroendocrine tumors, non-small cell lung cancer, small cell lung cancer and pancreatic adenocarcinoma patients. No tumor entity showed especially high levels of spleen [68Ga]Pentixafor uptake compared to others or a control cohort. However, when investigating laboratory parameters, there was a positive correlation of high spleen [68Ga]Pentixafor uptake with leukocyte and/or platelet counts in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer. CONCLUSION: Spleen [68Ga]Pentixafor uptake was not associated with stage of disease and clinical outcomes in solid tumor patients. We identified positively associated platelet and/or leukocyte counts with spleen [68Ga]Pentixafor uptake in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer, suggesting that splenic CXCR4 expression could possibly play a role in systemic immunity/inflammation in some types of solid tumors or a subgroup of patients within solid tumor entities.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Lewis R, Habringer S, Kircher M, et al. Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Res. 2021. PMID: 34417915. doi:10.1186/s13550-021-00822-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。